The early steps of differentiation of human B cells into plasma cells are poorly known. We report a transitional population of CD20 low/2 CD38 2 preplasmablasts along differentiation of human memory B cells into plasma cells in vitro. Preplasmablasts lack documented B cell or plasma cell (CD20, CD38, and CD138) markers, express CD30 and IL-6R, and secrete Igs at a weaker level than do plasmablasts or plasma cells. These preplasmablasts further differentiate into CD20 2 CD38 high CD138 2 plasmablasts and then CD20 2 CD38 high CD138 + plasma cells. Preplasmablasts were fully characterized in terms of whole genome transcriptome profiling and phenotype. Preplasmablasts coexpress B and plasma cell transcription factors, but at a reduced level compared with B cells, plasmablasts, or plasma cells. They express the unspliced form of XBP1 mRNA mainly, whereas plasmablasts and plasma cells express essentially the spliced form. An in vivo counterpart (CD19 + CD20 low/2 CD38 2 IL-6R + cells) of in vitro-generated preplasmablasts could be detected in human lymph nodes (0.06% of CD19 + cells) and tonsils (0.05% of CD19 + cells). An open access "B to Plasma Cell Atlas," which makes it possible to interrogate gene expression in the process of B cell to plasma cell differentiation, is provided. Taken together, our findings show the existence of a transitional preplasmablast population using an in vitro model of plasma cell generation and of its in vivo counterpart in various lymphoid tissues. The Journal of Immunology, 2011, 187: 3931-3941.
T he production of high-affinity Ig-producing plasma cells (PCs) is the end product of a complex network of cell interaction, gene rearrangements, and mutations. Ag encounter induces both B and T cells to move to the outer T cell zone, in which they interact each other. Activated B cells then migrate to follicles and initiate a germinal center (GC) reaction characterized by an extensive centroblastic proliferation associated with random somatic hypermutation in Ig genes (1) that are dependent on activation-induced deaminase (AID). CXCR4 + centroblasts are found within the dark zone of the GC, in close contact with poorly characterized dark zone follicular dendritic cells (FDCs) that do not produce CXCL13 (CXCR5 ligand) but express high levels of CXCL12 (CXCR4 ligand) (2, 3) . The internalization of CXCR4 after CXCL12 exposure allows the rapid CXCR5-dependent migration of centroblasts to the light zone, acquiring a centrocyte phenotype, and these centrocytes compete with each other for the capture of Ag presented as immune complexes by CXCL13 + light zone FDCs. B cells with high-affinity Ig will pick up greater amounts of Ag, thus receiving a BCR-mediated signal, together with a complex set of FDC-derived growth factors and adhesion molecules (3) (4) (5) . FDC/B cell interaction is short-lived but allows the capture of Ag for further presentation to a specific subset of GC-restricted follicular helper T cells (T FH ). T FH provide them with essential survival, class switch recombination, and differentiation signals, in particular CD40L and IL-21, that will contribute to the NF-kB/IRF4-dependent downregulation of BCL6 and the IRF4/STAT3-dependent upregulation of Blimp1. Owing to their lower affinity for Ag, the vast majority of centrocytes are not rescued by this FDC/T FH system and are engulfed by tingible body macrophages (6) . The GC is a dynamic structure, with GC B cells moving cyclically between the dark and light zones to undergo repeated rounds of mutation and selection (2, 7) . A successful selection will eventually promote GC B cells to give rise to early Ig secreting plasmablasts (PBs) or memory B cells (MBCs) under presently unknown signals. MBCs persist after immunization both as Ag-dependent memory within residual GC-like structures, in close contact to FDCs and T cells, and Agindependent memory dispersed outside B cell follicles (8) . In case of secondary immunization, MBCs can be restimulated to highly proliferate and differentiate into PBs and PCs.
The migration pattern of PBs has been recently documented in mice (9) . PBs travel through the T cell zone toward the medullary cords. They are first found in the outer T cell zone close to CD11c + CD8a 2 dendritic cells, which highly produce IL-6.
In vivo imaging has shown that PBs have a unique pattern of migration in T cell zone characterized by long linear paths that are randomly oriented (10) . This migration pattern is dependent on an integrin ICAM1/2 axis and independent on a chemokine gradient. Once arrived in the medullary zone, PBs further differentiate in contact with Gr1 + CD11b + F4/80 + monocytes/macrophages that highly produce CXCL12, APRIL, and IL-6 (9). PBs are retained in the medullary zone by the CXCL12 gradient but still keep moving. One putative reason of this continuous moving is to be able to share the limiting PC niche. Most PBs will die in medullary cords, and the surviving ones will exit the lymph node into lymphatic vessels through a SP1-dependent gradient (11) and enter the blood circulation in which they survive for a short period unless they can find a survival niche either in the bone marrow (BM), spleen, or mucosa-associated lymphoid tissues, in which they further differentiate into long-lived PCs (12) .
Several studies have contributed to better understand the process of differentiation of human centrocytes or MBCs into PBs and then mature PCs (reviewed in Ref. 13 ). The usual features of PBs are cell cycling, Ig secretion, high CD38 expression, and loss of B cell markers unlike CD19 (14) (15) (16) . Those of mature PCs are stop in cell cycle, Ig secretion, high CD38 expression, and CD138 proteoglycan expression (17) . We have shown that tonsil-purified CD20 + CXCR4 2 CXCR5 + centrocytes already express PC transcription factors (IRF4, Blimp-1, XBP1) together with B cell transcription factors (BCL6, PAX5), although it is not clear whether centrocytes are a heterogeneous cell population containing centrocytes and cells already committed to PC differentiation (18) . In an elegant study using cellular affinity matrix technology to capture secreted Igs, Arce et al. (19) (20) . Given their poor ability to survive upon CD40 activation removal, these CD38 2/low Ig-secreting cells were initially assumed to be early precursors of short-term surviving plasma cells (20) . In a following study, this group has shown that the ability to secrete Igs was mainly restricted to CD27 high cells, independently of CD38 expression (21) . Using a similar model of PC generation based on initial CD40L and oligodeoxynucleotide (ODN) activation of MBCs, we show in this study that CD38 2 CD20
2/low CD27 low Ig-secreting cells (termed preplasmablasts, prePBs) precedes the generation of CD38 high CD27
high PBs and then PCs. PrePBs fully survive and differentiate into PBs and PCs upon removal of CD40 activation. A full molecular and phenotypic characterization of prePBs is provided, showing that these cells express specifically CD30, IL-6R, and cytoplasmic Igs, express weakly CD27, do not express B cell or PC markers (CD38 and CD138), and secrete Igs at a lower level than do PBs or PCs. The in vivo counterpart of these prePBs could be found in various lymphoid tissues.
Materials and Methods

Reagents
Human recombinant IL-2 and IFN-a were purchased from R&D Systems (Minneapolis, MN), IL-6 and IL-15 were from AbCys (Paris, France), and IL-10 was from PeproTech (Rocky Hill, NJ). Mouse (or rat when indicated) mAbs conjugated to Alexa Fluor 488, Alexa Fluor 647, allophycocyanin, allophycocyanin-H7, allophycocyanin-Cy7, FITC, PerCPCy5.5, PE, and PE-Cy7 specific for human CD19 (clones HIB19 and SJ25C1), CD24 (clone ML5), CD27 (clones L128 and M-T271), CD30 (clone BerH8), CD38 (clone HIT2), CD43 (clone 1G10), CD45 (clone HI30), CD138 (clone MI15), CXCR5 (clone RF8B2), IgG (clone G18-145), IgM (clone G20-127), and Ki67 (clone B56) were purchased from BD Biosciences (Le Pont De Claix, France); CD20 (clone B9E9), CD126 (IL-6R, clone M91), and CD138 (clone B-A38) from were Beckman Coulter (Fullerton, CA); CCR10 (rat, clone 314305) was from R&D Systems; and IgG (polyclonal goat Ab) was from SouthernBiotech (Birmingham, AL).
Cell samples
Peripheral blood cells from healthy volunteers were purchased from the French Blood Center (Etablissement Français du Sang Pyrénnées-Médi-térannée, Toulouse, France). After removal of CD2 + cells using anti-CD2 magnetic beads (Invitrogen, Cergy Pontoise, France), CD19 + CD27 + MBCs were sorted with a multicolor fluorescence FACSAria device with a purity $ 95% (see Fig. 1A ). Cells produced in the culture system were FACSsorted using FITC-conjugated anti-CD20 mAb and PE-conjugated anti-CD38 mAb for day ( ) were FACS-sorted using FITC-conjugated anti-CD20 mAb and PE-conjugated anti-CD138 mAb. The purity of FACSsorted cell populations was $95% as assayed by cytometry. We looked for prePBs in tonsil, lymph node, BM, and peripheral blood samples. Tonsils were obtained from routine tonsillectomies performed at Chidren's Clinique La Sagesse at Rennes (France). Reactive nonmalignant lymph node biopsies were collected at Centre Hospitalier Universitaire de Rennes. After mincing, tonsillar and lymph node mononuclear cells were isolated by Ficoll-density gradient centrifugation. BM aspirates were collected from adult patients undergoing thoracic surgery (Centre Hospitalier Universitaire de Rennes) and BM mononuclear cells were isolated by Ficoll density gradient centrifugation. Tonsils, lymph node biopsies, and BM aspirates were all collected after subject recruitment followed Institutional Review Board approval and written informed consent process according to the Declaration of Helsinki.
Cell cultures
In step one, B cell activation, all cultures were performed in IMDM (Invitrogen) and 10% FCS (Invitrogen), supplemented with 50 mg/ml human transferrin and 5 mg/ml human insulin (Sigma-Aldrich, St Louis, MO). Purified MBCs were cultured with IL-2 (20 U/ml), IL-10 (50 ng/ml), and IL-15 (10 ng/ml) in six-well culture plates (1.5 3 10 5 /ml in 5 ml/well). Phosphorothioate CpG ODN 2006 (10 mg/ml; Sigma-Aldrich) (22) , histidine-tagged recombinant human soluble CD40L (sCD40L; 50 ng/ml) and anti-polyhistidine mAb (5 mg/ml) (R&D Systems) were added at culture start. In step two, PB generation, at D4 culture, the cells were harvested, washed, and seeded at 2.5 3 10 5 /ml with IL-2 (20 U/ml), IL-6 (50 ng/ml), IL-10 (50 ng/ml), and IL-15 (10 ng/ml). In step three, PC generation, at D7 culture, cells were washed and cultured at 5 3 10 5 /ml with IL-6 (50 ng/ml), IL-15 (10 ng/ml), and IFN-a (500 U/ml) for 3 d.
Cell cycle analysis and immunophenotypic analysis
The percentage of cells in the S phase of the cell cycle was determined using propidium iodide, and data were analyzed with ModFit LT software (Verity Software House, Topsham, ME) (23) . Cells were stained with combination of four to seven mAbs conjugated to different fluorochromes. Surface staining was performed prior to cell fixation and permeabilization. The Cytofix/Cytoperm kit (BD Biosciences) was used for intracellular staining of IgM, IgA, IgG, and Ki67 Ag, according to the manufacturer's recommendations. Flow cytometry analysis was performed with a FACSAria cytometer using FACSDiva 6.1 (Becton Dickinson, San Jose, CA) and with a Cyan ADP cytometer driven by Summit software (Beckman Coulter). For data analysis, CellQuest (Becton Dickinson), Summit, Kalusa (Beckman Coulter), and Infinicit 1.3 (Cytognos, Salamanca, Spain) softwares were used. The fluorescence intensity of the cell populations was quantified using the stain index (SI) formula: (mean fluorescence intensity obtained from the given mAb minus mean fluorescence intensity obtained with a control mAb)/(2 3 SD mean fluorescence intensity obtained with the same control mAb) (24) . The extensive phenotypic study of tonsil cells was carried out using the multicolor flow cytometry methodology and Abs we previously reported in detail (25) .
Analysis of Ig secretion
ELISPOT. D4 CD20 2 CD38 2 , D7 CD20 2 CD38 + , and D10 CD20 2 CD138 + cells were purified using cytometry cell sorting and cultured for 18 h in ELISPOT plates (Millipore, Bedford, MA), which were precoated with goat anti-human IgM, IgA, or IgG polyclonal Abs (Caltag Laboratories, Birlingame, CA). After nine PBS washings, alkaline phosphatase-conjugated goat anti-human IgM, IgA, or IgG Abs (Tebu-Bio, Le Perrayen-Yvelines, France) were added for 6 h at 37˚C. After three PBS washings, a mixture of NBT/5-bromo-4-chloro-3-indolyl phosphate substrate (Sigma-Aldrich) was added and reaction was stopped with distilled water. IgM-, IgA-, and IgG-secreting-cells were enumerated and immunospot size was assessed using the Biosys Bioreader 5000 apparatus (Biosys, Miami, FL).
, and D10 CD20 2 CD138
+ cells were cytometry cell sorted, cultured for 24 h, and culture supernatants were harvested. IgM, IgA, and IgG secretions were assessed by ELISA using goat anti-human Igs for coating and secondary HRP-conjugated Abs specific for human g-, a-, or m-H chains, respectively (all from Jackson ImmunoResearch Laboratories, Newmarket, U.K.) as previously described (18) .
Real-time RT-PCR analysis
Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA) and reverse transcribed with a reverse transcription kit (Qiagen). The Assays-onDemand primers and probes and the TaqMan Universal Master Mix were used according to the manufacturer's instructions (Applied Biosystems, Courtaboeuf, France). The primers used for assessing specific expression of spliced or unspliced forms of XBP1 mRNA were from Applied Biosystems (Hs0329085 and Hs02856596 primers). Real-time RT-PCR was performed using the ABI Prism 7000 sequence detection system and normalized to b 2 -microglobulin for each sample, and compared with the values obtained for a known positive control using the following equation: 100/2
DDCt
, where DDCt = DCt unknown 2 DCt positive control as described (26) .
Microarray hybridization and bioinformatic analysis
RNA was extracted and hybridized to human genome U133 Plus 2.0 GeneChip microarrays, according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). Gene expression data from D4 CD20 high CD38
2 cells, D4 CD20 low CD38 2 cells, and DCD20 2 CD38 2 cells are deposited in the ArrayExpress public database (http://www.ebi.ac.uk/ microarray-as/ae/, accession no. E-MEXP-3034). Gene expression data from D0 MBCs, D7 PBs, D10 PCs and purified BM PCs were from the ArrayExpress public database (http://www.ebi.ac.uk/microarray-as/ae/, accession number E-MEXP-2360). Gene expression data were analyzed with our bioinformatics platforms (RAGE, http://rage.montp.inserm.fr/) (27) and Amazonia (http://amazonia.transcriptome.eu/) (28). The clustering was performed and visualized with the Cluster and TreeView softwares (29) . Gene differentially expressed between cell populations was determined with the significance analysis of microarray (SAM) statistical microarray analysis software (30) .
Statistical analysis
Statistical comparisons were made with the nonparametric Mann-Whitney U test and the unpaired or paired Student t test using SPSS software. A p value of #0.05 was considered as significant. 
NA
MBCs were cultured as described in Fig. 1 . Starting MBCs and D4-activated cells were labeled with fluorochrome-conjugated anti-CD20 and anti-CD38 mAbs, and with fluorochrome-conjugated anti-human IgM, IgA, IgG, and Ki67 mAbs or isotype-controlled mAbs before or after cell permeabilization or with propidium iodide. For each cell population, data are the mean percentage 6 SD of positive cells and the mean staining indexes 6 SD from three to five separate experiments. 
Results
Activation of MBCs by sCD40L and CpG ODN yields two distinct cell populations
In the first step of differentiation of MBCs into PCs, two distinct cell populations could be identified in 17 separate experiments based on CD20 and CD38 expressions at the end of a 4-d activation by sCD40L and CpG ODN (step one). These two populations were CD20 high CD38 2 cells and CD20 low/2 cells comprising, respectively, 18 6 7 and 82 6 7% of D4 cells (Fig. 1B) The expression of surface (s) (sIgM, sIgA, sIgG) and cytoplasmic (cy) IgH isotypes (cyIgM, cyIgA, cyIgG) was looked for in the various D4 cell populations (Table I) . Starting MBCs comprised the expected percentages of sIgM + (43 6 12%), sIgA + (27 6 6%), and sIgG + (26 6 5%) cells (25, 31) , and cell permeabilization did not increase the cytometry SI significantly, indicating that MBCs expressed mainly sIgs (Table I ). In CD20 low CD38 2 , CD20 2 CD38 2 , and CD20 2 CD38 + cells, the SI with anti-IgM or anti-IgA Abs increased 10-to 20-fold after cell permeabilization (p , 0.05), indicating that these cells were strongly involved in cyIg production (Table I, Supplemental Fig. 1 ). The increase in SI with the anti-IgG mAb was significant (p , 0.05) but less pronounced (2-to 4-fold) due to the use of allophycocyanin-and PerCPCy5.5-fluorochome-conjugated Abs, resulting in a lower SI as reported (32 that Fig. 2A ), and with a 3-to 7-fold smaller immunospot size ($200 mm; Fig. 2B ). The number of IgA-secreting cells in D4 CD20 2 CD38 2 cells was not significantly different from those in D7 PBs or D10 PCs ( Fig. 2A ). There were 3-5% IgM-secreting cells in the D4 CD20 2 CD38 2 cell subset as in D7 PBs and D10 PCs ( Fig. 2A) , with no difference in IgM immunospot size. The measurement of Ig production in culture supernatants confirmed ELISPOT data. D4 CD20 2 CD38 2 cells secreted 5-to 7-fold less IgG, 1.5-to 2-fold less IgA, and similar IgM levels than did D7 PBs or D10 PCs (Fig. 2C) . Cell cycling was looked for with anti-Ki67 and propidium iodide staining (Table I) 
CD38
high PBs in four separate experiments (73 6 15 and 87 6 7%, respectively) in association with a 4.2-or 3.3-fold cell expansion, respectively (Fig. 3) . When further put into step three plasma cell culture conditions for 3 d (D7 to D10), the sorted CD20 low CD38 2 or CD20 2 CD38 2 cells generated CD20 2 CD38 high CD138 + PCs (51 6 7 and 72 6 5%, respectively; n = 4; Fig. 3 ). Conversely, D4 CD20 high CD38
2 cells gave rise to few CD38 + CD20 2 cells (23 6 13%, n = 4) in step two culture conditions, and did not survive when further put in step three plasma cell culture conditions (Fig. 3) Table II shows the top 50 genes that were upregulated in each of the two cell populations, and the 495 unique genes are shown in Supplemental factor and PAX5 target genes (IRF8, BACH2, EBF1, SPIB) (Fig.  6A, 6B ) as well as BCL6 gene (Fig. 6B) . CD20 low/2 prePBs expressed PC transcription factor genes PRDM1 and XBP1 at a weaker level than PBs or early PCs (Fig. 6A) . Because XBP1 mRNA has to be spliced by IRE1 endonuclease to encode for an active XBP1 protein (33) , spliced XBP1 (XBP1s) and unspliced (XBP1u) mRNAs were quantified. D4 prePBs expressed high levels of XBP1 mRNA, mainly XBP1u mRNA. The XBP1s/XBP1u mRNA ratio was 0.3 in prePBs, and this ratio was increased 3.5-to 5-fold in D7 PBs and D10 PCs that expressed XBP1s mRNA mainly (Fig. 6C) . The expression of genes coding for B cell and PC surface markers or homing molecules are displayed in Supplemental Figs. 2 and 3. Affymetrix data are in agreement with the phenotype of prePBs reported above: lack of B cell Ags and of CD38. Of interest, prePBs specifically expressed CD30 and EMP1 genes, unlike B cells, PBs, early PCs, or BMPCs. PrePB genes were significantly higher and B cell genes lower in CD20 2 prePBs than in CD20 low prePBs. MBCs were cultured as described in Fig. 1 . Cells were stained for CD20 and CD38 and the cell phenotype was analyzed by gating on D4 CD20 high CD38 2 cells, D4 CD20 low CD38 2 cells, and D4 CD20 MBCs were cultured as described in Fig. 1 . Starting MBCs, D4-activated cells were labeled with fluorochrome-conjugated anti-CD20 and anti-CD38 mAbs and with indicated fluorochrome-conjugated mAbs or isotype-controlled mAbs. For each cell population, data are the mean percentage 6 SD of positive cells and the mean staining indexes 6 SD from three to five separate experiments. expressed high levels of Ig L chains after cell permeabilization (Fig. 7B) . The other third expressed one log weaker levels of Ig L chain after cell permeabilization and we previously showed these cells are B cells that express surface Ig L chains (25) . Fig. 7C shows that a large part of in vivo CD19 + CD20 low/2 CD38 
Discussion
Owing to the rarity of plasma cells and their anatomic location, the early stages of differentiation of B cells into plasma cells are not fully elucidated, in particular in humans. Using an in vitro model mimicking T cell help, we report a transitional prePB stage in the differentiation of human memory B lymphocytes into PBs, and then plasma cells. These prePBs are characterized by the loss of B cell markers, except CD19, a decrease in CD27, the lack of CD38, and by the secretion of Igs at a lower level than CD38 activation by histidine-bound CD30L and anti-histidine Abs. No modulation was found in our culture conditions (data not shown). The loss of CD20 and most B cell markers in prePBs could be likely explained by the decrease in PAX5 that controls expression of B cell genes (34) (35) (36) . PAX5 gene expression decrease in prePBs is associated with an upregulation of expression of IRF4 and PRDM1 genes and downregulation of BCL6. Thus, the usual crossregulation of B and plasma cell transcription factors should occur in prePBs: NF-kB induces upregulation of IRF4 that associates with STAT3 to trigger PRDM1 gene activation and induces downregulation of BCL6 gene expression, an inhibitor of PRDM1 gene activation. The resulting expression of PRDM1 gene product, BLIMP1, further represses BCL6 and PAX5 genes, leading to the release of XBP1 gene suppression by PAX5. XPB1 mRNA has to be spliced by the IRE1 endonuclease to encode for XBP1 that masters the induction of the unfold protein response (33) . Pre-PBs expressed mainly XBP1u mRNA, and PBs and PCs expressed mainly the XBP1s mRNA with a 3.5-to 5-fold increase of the XBP1s/XBP1u mRNA ratio compared with prePBs. These data again argue for the prePB status of D4 CD20 low/2 CD38 2 cells that start to secrete Igs, but at a weaker level than PBs or PCs, and likely exhibit a less pronounced unfold protein response. An interesting point will be to identify the transcription factors controlling the transient CD30 gene expression in prePBs, and then the expression of CD38 and of its ligand, CD31, in PBs. Cells with the main characteristics of these in vitro PBs could be identified in tonsils and lymph nodes at a low frequency gating on CD19 + CD20 low/2 CD38 2 cells. They accounted for 0.06% and 0.05% of CD19 + cells in tonsils and positive lymph nodes, and they were not detected in peripheral blood and BM. We previously reported that PBs and B cells can be clearly identified by multicolor FACS analysis using cell permeabilization and anti-k or l Ig L chain staining (25) low/2 Ig-secreting cells in tonsils, unlike peripheral blood and BM. These in vivo cells expressed cytoplasmic Igs and IL-6R, as did in vitro prePBs, unlike tonsil or lymph node B cells. CD30 could not be detected on these prePBs in vivo. This could be due to a rapid shedding of the protein in vivo following activation by CD30L (37) .
Recent immunochemistry and in vivo imaging studies have documented the traffic of maturing plasma cells from GC to medullary cords in mice (9, 10) . In these studies, plasma cells were documented as IgG1-producing cells, which exit the GC to the outer T cell zone in contact with CD11c +
CD8a
2 dendritic cells producing IL-6. They then migrate randomly though linear paths in the T cell zone and join the medullary cords in contact with APRIL-producing monocytes/macrophages. These data fit well with the molecular characterization and phenotype of prePBs reported in this study. The need of T cell mimicking signals to get them in vitro suggests they are generated in the GC light zone in vivo. The loss of CXCR5 expression in prePBs should abrogate the attraction of these cells by CXCL13 producing FDC and T FH and CD40L activation and promote their migration to the outer T cell zone. IL-6R expression by prePBs will prompt them to be stimulated by IL-6-producing CD11c + CD8a 2 dendritic cells. Of note, a removal of CD40L activation and a stimulation by IL-6 are mandatory to induce prePBs to differentiate into PBs in the current in vitro model (31) , suggesting that this occurs in vivo when prePBs migrate from GC light zone to CD11c + CD8a 2 dendritic cells producing IL-6, which are found at the GC/T cell zone border (9) . The current identification of Ig-producing prePBs, lacking CD20 and CD38, would allow for the precise location and traffic of these prePBs, compared with CD38 + PBs and then CD38 + CD138 + plasma cells. PrePBs also express LFA-1 (ITGAL/ ITGB2) and VLA-4 (ITGA4/ITGB1) integrins that could drive plasma cell motility within lymph node through ICAM1/2 or VCAM-1 gradient (10, 38) .
In conclusion, we have fully characterized a human transitional prePB stage. This opens the possibility to elucidate the mechanisms controlling their generation, to track these prePBs in the process of normal plasma cell differentiation in vivo, after immunization to a given Ag, and to look for cancer disease characterized by the immortalization of the prePBs.
